Anti-IL-13Rα1 antibodies and their uses thereof
US8613925B2 · kind B2 · utility
1Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 19, 2007 |
| Grant date | Dec 24, 2013 |
| Priority date | — |
| Expiry date | Oct 11, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13Rα1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13Rα1-mediated activities are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.